Invention Grant
US08962265B2 Mutant parasites for use as vaccines and platforms for screening for compounds 有权
突变型寄生虫用作疫苗和筛选化合物的平台

Mutant parasites for use as vaccines and platforms for screening for compounds
Abstract:
Cloning and characterization of a TgIF2α kinase from Toxoplasma gondii designated TgIF2K-D illustrates that this protein is related to GCN2, an eIF2α kinase known to respond to nutrient starvation in other organisms. TgIF2K-D is present in the cytosol of both intra- and extracellular Toxoplasma and facilitates translational control through TgIF2α phosphorylation in extracellular parasites. Both a TgIF2K-D knockout parasite and a parasite harboring the TgIF2α mutant (S71A substitution) exhibited loss of eIF2α kinase activity which manifested itself as significant fitness defect. Accordingly, eIF2α phosphorylation and translational control are an important mechanism by which vulnerable extracellular parasites protect themselves which searching for a new host cell. TgIF2K-D is an excellent target for development of compounds and therapies that can be used to treat infections caused by Toxoplasma and other eukaryotic parasites, especially parasites that have high homology or identity to TgIF2K-D.
Information query
Patent Agency Ranking
0/0